Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shai Shimony

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Leukemia Research|July 14, 2023
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemiaMaximilian Stahl, Gerard Giblin, Yiwen Liu, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Targetable leukemia dependency on noncanonical PI3Kγ signalingQingyu Luo, Evangeline G Raulston, Miguel A Prado, et al.
Blood Advances|January 15, 2026
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 CriteriaShai Shimony, Yating Wang, Angel M Cronin, et al.
The American Journal of Surgical Pathology|April 20, 2026
The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid NeoplasmsSarah J Wu, Christopher B Hergott, Gabriel K Griffin, et al.
Nature|May 8, 2024
Targetable leukaemia dependency on noncanonical PI3Kγ signallingQingyu Luo, Evangeline G Raulston, Miguel A Prado, et al.
British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.
Blood|July 7, 2026
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell NeoplasmAndrew A Lane, Marlise R Luskin, Julia H Keating, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Leukemia Research|July 14, 2023
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemiaMaximilian Stahl, Gerard Giblin, Yiwen Liu, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Targetable leukemia dependency on noncanonical PI3Kγ signalingQingyu Luo, Evangeline G Raulston, Miguel A Prado, et al.
Blood Advances|January 15, 2026
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 CriteriaShai Shimony, Yating Wang, Angel M Cronin, et al.
The American Journal of Surgical Pathology|April 20, 2026
The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid NeoplasmsSarah J Wu, Christopher B Hergott, Gabriel K Griffin, et al.
Nature|May 8, 2024
Targetable leukaemia dependency on noncanonical PI3Kγ signallingQingyu Luo, Evangeline G Raulston, Miguel A Prado, et al.
British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.
Blood|July 7, 2026
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell NeoplasmAndrew A Lane, Marlise R Luskin, Julia H Keating, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Pageof 8